SLLK, Control Peptide for TSP1 Inhibitor(TFA)
| 中文名称 | SLLK, Control Peptide for TSP1 Inhibitor(TFA) |
|---|---|
| 中文同义词 | |
| 英文名称 | SLLK, Control Peptide for TSP1 Inhibitor(TFA) |
| 英文同义词 | SLLK, Control Peptide for TSP1 Inhibitor(TFA) |
| CAS号 | |
| 分子式 | C??H??F?N?O? |
| 分子量 | 0 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | Mol File |
| 结构式 |
SLLK, Control Peptide for TSP1 Inhibitor(TFA) 性质
| 形态 | 固体 |
|---|---|
| 颜色 | 白色至米白色 |
| 序列 | H-Ser-Leu-Leu-Lys-NH2 |
SLLK, Control Peptide for TSP1 Inhibitor (TFA) 是血小板反应蛋白抑制剂 (TSP-1) LSKL 的对照肽。
纯度(HPLC) ≥98.0%
醋酸根含量≤12.0%
水分含量≤8.0%
肽含量≥80.0%
内毒素≤50EU/mg
氨基酸组成分析≤±10%
Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold, compared with renal lysates from either saline controls or SLLK-treated mice.TGF-β1 is significantly lower (0.10±0.01 pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice receiving SLLK control peptide at day 42 (0.20±0.02 pg/mL; P=0.0001). MRNA expression is assessed in the suprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides.
多肽
SLLK是血小板反应蛋白抑制剂(TSP-1)?LSKL的对照肽，是一条由四个氨基酸组成的短肽，其中多肽的C端被酰胺键封闭，具有较好的稳定性。参考质量标准
外观:白色粉末纯度(HPLC) ≥98.0%
醋酸根含量≤12.0%
水分含量≤8.0%
肽含量≥80.0%
内毒素≤50EU/mg
氨基酸组成分析≤±10%